IMF Recorded Program

Read the Opinions of Our Experts

Proven Approaches to Preventing Hypoglycemia
Brian Frier, BSc, MD, FRCP(Edin)
Edinburgh, Scotland, United Kingdom

Fixed-dose Combinations in the Management of Type 2 Diabetes 
Abdullah Bennakhi, MD
Kuwait City, Kuwait

The Impact of Uncontrolled Diabetes on Overall Cardiovascular Health
Naveed Sattar, MD
Glasgow, Scotland, United Kingdom 

The Global Burden of Diabetes: Challenges and Advances
Andrew JM Boulton, MD, DSc, FICP, FACP, FRCP
Manchester, England, United Kingdom

New Type 2 Diabetes Treatment Options: Optimizing Results Amidst the COVID-19 Pandemic 
Shashank R. Joshi, MD, DM, FRCP, FACE, FACP, FICP, FICN
Mumbai, Maharashtra, India

Program Information

The treatment of type 2 diabetes mellitus has evolved in the present century toward safer and more effective treatments, which in some cases can also reduce the risk of hypoglycemia, cardiovascular disease and renal outcomes.  New glucose-lowering drugs acting on novel pathways, as well as new formulations, have been developed, licensed and launched, many of which provide new options for the management of type 2 diabetes.  However, there is a rising prevalence of type 2 diabetes and its associated comorbidities, posing new challenges for health care practitioners.  These challenges are that much more demanding during the unprecedented COVID-19 pandemic. 

This interactive webinar will review the novel mechanisms of action and pharmacokinetics of these agents and will also address how reaching appropriate therapeutic goals for the type 2 diabetes patient is possible. Four short presentations by prominent leaders in the fields of endocrinology and cardiology will focus on topics that will enable practitioners to implement new therapeutic strategies. 

Learning Objectives

Based on the information presented during this live program, upon the webinar’s conclusion participants will be able to: 

  • Recognize the association between glycemic variability as a predictor of hypoglycemia, the clinical implications of hypoglycemia in type 2 diabetes patients, and proven approaches to its prevention
  • Explain the role of fixed dose combination therapy and when and how it is appropriate to adjust insulin therapy in type 2 diabetes patients, as well as manage clinical inertia
  • Implement new treatment strategies with evidence provided by recent cardiovascular outcomes trials that highlight new therapies that have a demonstrated decrease in cardiovascular risk 
  • Understand the special considerations for patients with type 2 diabetes in light of the COVID-19 pandemic

Meet the Faculty

Andrew J.M. Boulton, MD, DSc, FICP, FACP, FRCP (Program Chair)
Professor of Medicine, University of Manchester and
Consultant Physician, Manchester Royal Infirmary
Manchester, England, United Kingdom
Visiting Professor of Medicine, University of Miami Miller School of Medicine
Miami, Florida, United States
Chairman, EURADIA (The European Alliance for Diabetes Research)
President, International Diabetes Federation
Member of the Board of Directors, Worldwide Initiative for Diabetes Education

Brian M. Frier, BSc, MD, FRCP(Edin)
Honorary Professor of Diabetes
BHF Centre for Cardiovascular Science
The Queen’s Medical Research Institute
University of Edinburgh
Edinburgh, Scotland, United Kingdom

Abdullah Bennakhi, MD
Consultant Physician Diabetologist
Chair of the Regulatory Affairs Office and Ethical Review Committee
Dasman Diabetes Institute
Kuwait City, Kuwait

Naveed Sattar, MD
Professor/Honorary Consultant
Cardiovascular & Medical Sciences
University of Glasgow
Glasgow, Scotland, United Kingdom

Shashank R. Joshi, MD, DM, FRCP, FACE, FACP, FICP, FICN
Professor and Senior Consultant
Lilavati Hospital
Mumbai University
Mumbai, Maharashtra, India

Webinar Agenda

20:00 – 20:05Introduction and Program ObjectivesAndrew J.M. Boulton, MD, DSc, FICP, FACP, FRCP (Chair)
20:05 – 20:20Proven Approaches to Preventing HypoglycemiaBrian Frier, BSc, MD, FRCP(Edin)
20:20 – 20:35Fixed Dose Combinations and Other Strategies to Managing Type 2 DiabetesAbdullah Bennakhi, MD
20:35 – 20:50The Impact of Uncontrolled Type 2 Diabetes on Overall Cardiovascular Health Naveed Sattar, MD
20:50 – 21:05New Type 2 Diabetes Treatment Options: Optimizing Results Amidst the COVID-19 Pandemic Shashank Joshi, MD, DM, FRCP, FACE
21:05 – 21:20 Live Discussion of Questions Submitted per Worldwide Diabetes-IFM Pre-Webinar BlogModerated by the webinar chair
21:20 – 21:30Panel Discussion / Question & Answer SessionAll Speakers

Register and Access the One-Demand Program

Click here to register and access the on-demand webinar.

This program is sponsored by the Worldwide Initiative for Diabetes Education and supported by an educational grant from Novo Nordisk A/S.